Safety and Efficacy of Percutaneous Coronary Intervention Combined With Thrombolysis at Different Time

Inclusion Criteria: * Aged 19 to 70 years old, gender not limited * 30 minutes or more persistent ischemia chest pain, and symptoms can't ease by treated by nitroglycerin * In two or more lead ecg ST-segment（the line between QRS complex finish point and the start point of T wave in electrocardiogram) elevation ≥ 0.1mv, or two or more than two neighboring chest lead ST-elevation ≥0.2mv * Persistent ischemia chest pain less than 6 hours, door to balloon time\>90 minutes and transfer time \>120 minutes * Accept coronary arteriography and intervention treatment * Signed informed consent Exclusion Criteria: * Pregnancy and lactation, menstrual period women * Blood disease, clotting hemorrhagic disease, any part of active bleeding or bleeding tendency physique * History of trauma in two months, including biopsy and received surgical operation * History of the great vessels punctured in two weeks that could not oppression * History of ischemic or hemorrhagic stroke and cerebrovascular accident * Cardiac shock,reinfarction again, right ventricular myocardial infarction, history of cardiopulmonary resuscitation (CPR) * History of PCI or coronary artery bypass grafting（CABG） * Killip classification level III（a standard of heart function classification） or above, or cardiac mechanical complications such as cardiac rupture * History of eyeground hemorrhage * Currently use of therapeutic doses of anticoagulants, such as warfarin, etc * Uncontrolled hypertension, systolic blood pressure before thrombolysis is still 160 mmHg or higher, diastolic blood pressure is still 100 mmHg or higher * Active internal bleeding (such as gastrointestinal bleeding), urogenital system, or have not cure of peptic ulcer in four weeks * Severe liver and kidney dysfunction * Intracranial tumor, suspicious aortic dissection, arteriovenous malformation, aneurysm * Thrombolysis treatment in one week * Allergies of thrombolysis drug or contrast * Participated in any clinical trials within three months